(Q37118186)

18 August 2017

1 reference

title

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines (English)

1 reference

18 August 2017

0 references

2

F Stephen Hodi

1 reference

18 August 2017

1

Masahisa Jinushi

1 reference

18 August 2017

Glenn Dranoff

3

1 reference

18 August 2017

publication date

1 April 2008

1 reference

18 August 2017

published in

Immunological Reviews

1 reference

18 August 2017

volume

222

1 reference

18 August 2017

page(s)

287-298

1 reference

Cytokines in cancer pathogenesis and cancer therapy

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

NF-kappaB: linking inflammation and immunity to cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Smoldering and polarized inflammation in the initiation and promotion of malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

COX-2 inhibition and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Paradoxical roles of the immune system during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Stromal fibroblasts in cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Vaccines for tumour prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Cancer vaccines: between the idea and the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

A blast from the past: clearance of apoptotic cells regulates immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Clearance of apoptotic cells: getting rid of the corpses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Phosphatidylserine recognition by phagocytes: a view to a kill

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Identification of a factor that links apoptotic cells to phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Expression of developmental endothelial locus-1 in a subset of macrophages for engulfment of apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Phagocytosis and clearance of apoptotic cells is mediated by MER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

IL-23 promotes tumour incidence and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Th17: an effector CD4 T cell lineage with regulatory T cell ties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Lactadherin promotes VEGF-dependent neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Integrin signalling during tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Integrin signaling is critical for pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Twist mediates suppression of inflammation by type I IFNs and Axl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The emerging role of CTLA-4 as an immune attenuator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Combinatorial cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Roles of the NKG2D immunoreceptor and its ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Recruiting dendritic cells to improve antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The DNA damage response arouses the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The new B7s: playing a pivotal role in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

MFG-E8/Lactadherin Promotes Tumor Growth in an Angiogenesis-Dependent Transgenic Mouse Model of Multistage Carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00618.X

10.1111/J.1600-065X.2008.00618.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference